Revelation Biosciences (REVB) Stock Price, News & Analysis

Company Overview

Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products. The company’s programs and collaborations are intended to support the potential use of its therapies in the United States and broader international markets, subject to regulatory approval.

Key Stats

• Today's Range: $4.28 to $4.50
• 50-Day Range: $3.29 to $7.16
• 52-Week Range: $3.08 to $40.60
• Volume: 2,505 shs
• Average Volume: 33,335 shs
• Market Capitalization: $2.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Revelation Biosciences Stock Analysis - MarketRank™

Revelation Biosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Revelation Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Revelation Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Revelation Biosciences are expected to grow in the coming year, from ($35.08) to ($10.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revelation Biosciences is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revelation Biosciences is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Revelation Biosciences has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.96% of the float of Revelation Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Revelation Biosciences has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revelation Biosciences has recently increased by 93.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revelation Biosciences does not currently pay a dividend.

Dividend Growth

Revelation Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.08

News Sentiment

Revelation Biosciences has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Revelation Biosciences this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revelation Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Revelation Biosciences is held by insiders.

Percentage Held by Institutions

12.80% of the stock of Revelation Biosciences is held by institutions.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:REVB
• CIK: 1810560
• Web: www.revbiosciences.com
• Phone: 650-800-3717
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($42.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.91 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -124.23%
• Return on Assets: -98.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.98
• Quick Ratio: 6.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.59 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 680,000
• Free Float: 650,000
• Market Cap: $2.90 million
• Optionable: Not Optionable
• Beta: -0.13